Sutent Capsule
Product Images NDC 0069-0830

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sutent (NDC 0069-0830). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Sutent 01)

Chemical structure of Sunitinib malate, the active ingredient in SUTENT capsules. The diagram shows the molecular composition including its malate salt form, represented with chemical bonds and atomic symbols.*

FDA Label Image

Figure 1 (Sutent 02)

Kaplan-Meier curve showing time to tumor progression probability over weeks for SUTENT versus placebo. The graph compares tumor progression rates in patients treated with SUTENT (N=207) and placebo (N=105), indicating median progression times of 27.3 and 6.4 weeks respectively, with statistical measures including hazard ratio, confidence interval, and p-value.*

FDA Label Image

Figure 2 (Sutent 03)

A Kaplan-Meier survival curve chart comparing progression-free survival probability over time (in weeks) between two groups: SUTENT (N=375) and IFN-α (N=375). The SUTENT group shows a higher median progression-free survival of 47.3 weeks versus 22.0 weeks for IFN-α. The chart includes a hazard ratio of 0.42 with a 95% confidence interval (0.32, 0.54) and a p-value less than 0.000001, indicating statistical significance. The number of subjects at risk at various time points is listed below the graph.*

FDA Label Image

Figure 3 (Sutent 04)

A survival probability line chart comparing disease-free survival over time (years) between SUTENT (N=309) and a placebo group (N=306). The graph shows SUTENT with a median disease-free survival of 6.8 years and placebo 5.6 years, including a hazard ratio of 0.76 with 95% confidence interval (0.59, 0.98) and a P-value of 0.03. Numbers at risk for both groups are displayed for each time point up to 8 years.*

FDA Label Image

Figure 4 (Sutent 05)

A Kaplan-Meier curve chart showing progression-free survival probability over time (months) comparing SUTENT capsules versus placebo in a clinical trial. The solid line represents SUTENT (N=86) with a median progression-free survival of 10.2 months, and the dashed line represents placebo (N=85) with a median of 5.4 months. The chart includes a hazard ratio with confidence interval and p-value, and a table of subjects at risk at different time points below the x-axis.*

FDA Label Image

Pfizer Logo (Sutent 06)

FDA Label Image

Pfizer Logo (Sutent 07)

FDA Label Image

Principal Display Panel (12.5 mg Capsule Bottle Label)

SUTENT 12.5 mg capsules label with sunitinib malate as the active ingredient. The package contains 28 capsules and is marked Rx only. Manufactured by Pfizer Laboratories Div Pfizer Inc. Storage instructions and dosage warnings are visible along with barcode and GTIN numbers.*

FDA Label Image

Principal Display Panel (25 mg Capsule Bottle Label)

Label for Sutent capsules containing sunitinib malate, 25 mg strength. The label states the product is manufactured by Pfizer Laboratories Div Pfizer Inc, with 28 capsules per package. It includes storage instructions (20°C to 25°C), dosing notes, barcode, and a note to dispense with a medication guide. The label also features lot and expiration placeholders and a separate green section indicating online printing information with date and serial number fields.*

FDA Label Image

Principal Display Panel (50 mg Capsule Bottle Label)

Sutent 50 mg capsules label, containing sunitinib malate, an oral prescription drug by Pfizer Laboratories. The label indicates 28 capsules per container. Storage instructions specify 20°C to 25°C with allowable excursions. The packaging includes barcodes, NDC 0069-0980-38, and standard dispensing and dosage use statements.*

FDA Label Image

Principal Display Panel (37.5 mg Capsule Bottle Label)

Label for Sutent (sunitinib malate) capsules, 37.5 mg strength. The label shows Pfizer as the labeler and indicates the package contains 28 oral capsules. It includes storage instructions, dosage notes, NDC 0069-0830-38, barcodes, and a lot/expiration date area, along with a green printed line section with placeholders for additional coding.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.